In Italy, the highest number of new diagnoses of vulva cancer was identified among women above 85 years, with *** new cases in 2020. This statistic shows the number of women with a new diagnosis of vulva cancer in Italy in 2020, by age group.

Background: The incidence of vulvar cancer in Germany is increasing. Moreover, gynaecological oncologists reported observing increasing numbers of women presenting with small tumours. The aim of the present study is to validate this observation on a population level and to extend available incidence data. Material and methods: Data from the population-based Saarland Cancer Registry were used and included 1136 women diagnosed with invasive vulvar cancer (ICD-9 codes: 181.1-181.4, ICD-10 code: C51) between 1974 and 2013. Multiple imputation methodology was used to overcome loss of precision and potential bias resulting from incomplete data. Incidence trends were investigated with regard to age at diagnosis, tumour size and clinical stage, morphology and histopathologic grade. Results: The age-standardised incidence rate of vulvar cancer increased from 1.6 cases per 100,000 women per year in 1974–78 to 7.9 in 2009–13, representing an increase across all age groups. Since 1989–93, an almost exclusive increase in the incidence of small tumours ≤2 cm in the greatest dimension from 1.2 to 6.6 and of squamous cell carcinomas from 1.7 to 7.1 was observed, whereas the number of larger tumours and other invasive cancers remained rather constant. Patients aged ≥75 years generally suffered from more advanced tumours at the time of diagnosis. Conclusions: An increase in vulvar cancer incidence of a size as observed in this study has not been reported thus far for any other European region. Furthermore, the analyses confirmed the observation of increasing numbers of women presenting with small tumours. The results of the age-specific analyses point to both human papillomavirus infection and non-infectious factors as explanations for the observed increase in squamous cell carcinomas.

In Italy, the highest number of deaths from vulva cancer was among women above 85 years, with *** deaths in 2020. This statistic shows the number of deaths from vulva cancer among women in Italy in 2020, by age group.

Users can access data about cancer statistics in the United States including but not limited to searches by type of cancer and race, sex, ethnicity, age at diagnosis, and age at death. Background Surveillance Epidemiology and End Results (SEER) database’s mission is to provide information on cancer statistics to help reduce the burden of disease in the U.S. population. The SEER database is a project to the National Cancer Institute. The SEER database collects information on incidence, prevalence, and survival from specific geographic areas representing 28 percent of the United States population. User functionality Users can access a variety of reso urces. Cancer Stat Fact Sheets allow users to look at summaries of statistics by major cancer type. Cancer Statistic Reviews are available from 1975-2008 in table format. Users are also able to build their own tables and graphs using Fast Stats. The Cancer Query system provides more flexibility and a larger set of cancer statistics than F ast Stats but requires more input from the user. State Cancer Profiles include dynamic maps and graphs enabling the investigation of cancer trends at the county, state, and national levels. SEER research data files and SEER*Stat software are available to download through your Internet connection (SEER*Stat’s client-server mode) or via discs shipped directly to you. A signed data agreement form is required to access the SEER data Data Notes Data is available in different formats depending on which type of data is accessed. Some data is available in table, PDF, and html formats. Detailed information about the data is available under “Data Documentation and Variable Recodes”.

ObjectivesTime trends on the incidence and characteristics of invasive vulvar cancer in Germany have so far been studied in few local population- and hospital based tumor registries. We aimed to provide an overview on recent developments of vulvar cancer in Germany, using population-based cancer registry data.MethodsWe analyzed the data on vulvar cancer of eight population-based German cancer registries for the period 1999-2011. ICD-10 codes and ICD-O-3 morphology codes were used to select site and histologic types. The annual percentage change was calculated on age-adjusted incidence rates with a joinpoint regression model.ResultsA total of 12,711 registered cases of invasive carcinoma of the vulva were included in the analyses, hereof were 12,205 of squamous cell origin. Age-standardized incidence rates of vulvar cancer annually increased by 6.7% (95% confidence limits: 5.6-7.9) from 1.7 per 100,000 women in 1999 to 3.6 per 100,000 women in 2011. An increase was observed among women of all ages, and especially between 30 and 69 years of age.ConclusionThe annual incidence of invasive carcinoma of the vulva nearly doubled in the past decade in Germany, considerably exceeding the rates observed in other Western European countries. A combination of changes in risk factors, and documentation practice might have contributed to the observed substantial increase in vulvar cancer incidence.

The size of the Vulvar Cancer Market was valued at USD 12.75 billion in 2023 and is projected to reach USD 23.16 billion by 2032, with an expected CAGR of 8.90% during the forecast period. Recent developments include: Novartis, a Swiss-based corporation, introduced Oncofocus, the world's most precise oncology test for detecting the kind of cancer, increasing the likelihood of effective therapy., On January 1, 1891, George Merck, at 23 years old, established Merck & Co in the United States to distribute excellent chemicals across New York City and the surrounding areas. In the pursuit of their purpose to save and improve lives, they have been creating for life, bringing forth medicines and vaccines for many of the world's most difficult diseases., With 74,000 workers and USD 13.6 billion in research and development, Merck & Co. shows their dedication to patients and public health by expanding access to health care through far-reaching policies, programs, and collaborations., It also analyses trends and co-development arrangements to find business opportunities in the Vulvar Cancer Market. Product mapping is available for all major market participants' important products. It also aids firms in complying with current health and safety laws. The study breaks down the industry into several sectors and delivers the most accurate revenue estimates for the overall market across various geographies. In this research analysis, the global market potential, industry dynamics, and leading vendors operating in the market are all covered in depth.. Key drivers for this market are: Advancements in targeted therapies and increasing awareness about early detection.

. Potential restraints include: High treatment costs and limited awareness in low-income regions.

. Notable trends are: Emergence of personalized medicine and immunotherapies.

.

Staging limited to data from 1999–2009 (TNM editions 4–6).aThe average annual percentage change (AAPC) from 1999–2011 of the age standardized (old European standard) incidence rate (ASIR).Women’s age at diagnosis and characteristics of the invasive vulvar tumors diagnosed from 1999–2011 (for topography up to 2009).

aCIN2/3 and AIS - cervical intraepithelial neoplasia grade 2 and 3 and adenocarcinoma in situ.bVIN2/3 - vulvar intraepithelial neoplasia grade 2/3.cVaIN2/3 - vaginal intraepithelial neoplasia grade 2/3.*from Sweden only grade 3 VIN and VaIN were included.

Explore the dynamic Vulvar Cancer Treatment market, projected to reach USD 9,140 million by 2033 with a 7.5% CAGR. Discover key drivers, trends, and market segmentation for advanced cancer therapies.

The vulvar cancer market is projected to be valued at $650 million in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 6.5%, reaching approximately $1.2 billion by 2034.

The global gynecological cancer diagnostics market is booming, projected to reach $8.5 billion by 2033, driven by rising cancer rates and advanced technologies. Learn about market trends, key players, and future growth potential in this in-depth analysis.

The size of the Vulvar Cancer Treatment market was valued at USD 62 million in 2024 and is projected to reach USD 88.41 million by 2033, with an expected CAGR of 5.2% during the forecast period.

Supplemental Figure 3 (A-D): Demographic and Socioeconomic Disparities in VSCC Overall Survival (A) Kaplan-Meier survival curves illustrating survival differences by geographic location, with better survival in metropolitan areas. (B) Kaplan-Meier survival curves displaying survival outcomes stratified by income, highlighting significantly worse survival in lower-income groups. (C) Kaplan-Meier survival curves assessing survival by marital status, showing the best outcomes among married patients and the poorest outcomes among widowed patients. (D) Kaplan-Meier survival curves demonstrating survival differences by age, illustrating a steady decline in survival with increasing age, particularly after 50 years.

Supplemental Table 1: Demographic and Clinicopathologic Profile of Vulvar Squamous Cell Carcinoma

The Vulvar Cancer Treatment market is a vital segment of the broader oncology landscape, focused on addressing the unique challenges associated with vulvar cancer- a relatively rare yet impactful form of cancer that affects the external genitalia of women. This market encompasses a variety of treatment options, incl

The gynecological cancers drug market is booming, projected to reach $56.65 billion by 2033, driven by rising incidence rates and advancements in targeted therapies. Explore market trends, key players (GlaxoSmithKline, Eli Lilly, etc.), and future growth projections in this comprehensive analysis.

IntroductionHPV infection is a common risk factor for all anogenital cancers. However, there are important differences in the epidemiology of anogenital cancers and these have not been compared considering diverse epidemiological indicators over a long period of time. To fill this gap, we investigated incidence, mortality, and survival trends of anogenital cancers over a period of three decades.MethodsWe conducted an observational registry-based study using data from the population-based cancer registry of Granada in southern Spain. We collected data on all incident cases of anogenital cancer (cervical, anal, penile, vulvar, and vaginal cancer) diagnosed between 1985 and 2017. We calculated crude and age-standardized incidence and mortality rates, and 1, 3, and 5-year overall and net survival. We further conducted time-trend analysis calculating annual percent changes (APC) for each cancer site.ResultsThe incidence of anogenital cancers decreased slightly during the past 30 years, with the exception of vulvar cancer, where a slight increase was observed. Mortality decreased significantly for cervical cancer over the study period but increased non-significantly for the remaining cancer sites. Survival rates were similar to those reported in comparable countries and increased for cervical and vulvar cancer.DiscussionCervical cancer was the greatest contributor to the burden of anogenital cancers and showed a marked improvement in all indicators in comparison to the remaining cancer sites.

Numbers represent annual age-standardized incidence rates per 100,000 women (old European Standard) of invasive vulvar cancer in selected national population-based cancer registries.aRegion Flamish only.DCO cases, melanoma, and histologically not further specified cases included.

Yearly citation counts for the publication titled "Immune Profiling of Vulvar Squamous Cell Cancer Discovers a Macrophage-rich Subtype Associated with Poor Prognosis".

The gynecological cancer diagnostics market is booming, driven by rising cancer rates, advanced technologies, and home testing kits. Explore market trends, key players (Roche, Myriad Genetics), and growth projections in this in-depth analysis covering various cancer types and diagnostic methods. Discover the impact of genetic counseling tests, cancer risk assessments, and regional variations in this expanding sector.